Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy

Allergy and Asthma Proceedings

Volumn 28, Issue 3, 2007, Pages 313-319

  Price, Kursteen S ^a   Hamilton, Robert G ^b  

^a Allergy Asthma and Dermatology Associates   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaphylaxis; Asthma; Epicutaneous skin testing; Free total IgE; IgE anti omalizumab; IgG anti omalizumab; Intradermal skin testing; Omalizumab; Polysorbate; Serology

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; EXCIPIENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OMALIZUMAB; POLYSORBATE; RECOMBINANT PROTEIN;

ANAPHYLAXIS; ARTICLE; ASTHMA; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; IMMUNOLOGY; INTRACUTANEOUS TEST; MIDDLE AGED;

ALLERGENS; ANAPHYLAXIS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; EXCIPIENTS; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTRADERMAL TESTS; MIDDLE AGED; POLYSORBATES; RECOMBINANT PROTEINS;

EID: 34447266193     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.3003     Document Type: Article

References (14)

1. Finkelman FD, Rothenberg ME, Brantdt EB, et al. Molecular mechanisms of anaphylaxis: Lessons from studies with murine models. J Allergy Clin Immunol 115:449-457, 2005.
2. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115:459-465, 2005.
3. Berger W, Gupta N, McAlary, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 91:182-188, 2003.
4. Demoly P, Piette V, and Bousquet J. In vivo methods for study of allergy: Skin tests, techniques and interpretation. In Middleton's Allergy Principles and Practice, 6th ed. Chap. 38. Adkinson NF Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, and Simons FER (Eds). St. Louis: Mosby, 631-643, 2003.
5. Hamilton RG. Accuracy of Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 117:759-766, 2006.
6. Hamilton RG, Marcotte GV, and Saini SS. Immunological methods for quantifying free and total serum IgE in asthma patients receiving omalizumab (Xolair) therapy. J Immunol Methods 303:81-91, 2005.
7. Hamilton RG. Assessment of human allergic diseases. P. 124.1-124.14 in Clinical Immunology, 2nd ed., Chap. 124. Rich RR, Fleisher TA, Shearer WT, Schroeder HW, and Kotzin B (Eds). St. Louis: Mosby; London: Harcourt Health Sciences, London, 2001.
8. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973, 1999.
9. Ruffin CG, and Busch BE. Omalizumab: A recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm 61:1449-1459, 2004.
10. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34:10474-10482, 1995.
11. Coors EA, Seybold H, Merk HF, et al. Polysorbate 80 in medical products and non-immunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 95:593-599, 2005.
12. ten Tijr AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685, 2003.
13. Dreyfus DH, and Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 96:624-627, 2006.
14. Lanier BQ. Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc 26:435-439, 2005.